Retatrutide: The 30% Drug

A Drug That Erases a Third of You

I covered retatrutide back in Issue #016, when all we had was a 338-person Phase 2 trial and a great deal of breathless extrapolation. I called it the most promising weight-loss molecule in development, and I told you to wait for the Phase III data before you believed the headline number. The Phase III data is now here. As of this morning, all three of the program's first pivotal trials have reported — and the headline number got bigger, not smaller.

In TRIUMPH-1, the pivotal obesity trial Eli Lilly reported today, adults without diabetes lost an average of 28.3% of their body weight on the 12-milligram dose over 80 weeks. In a pre-specified severe-obesity extension, that figure climbed to 30.3% at 104 weeks, with the average patient on the top dose shedding about 85 pounds.¹ No drug has done this in a randomized trial. That is weight loss in the territory historically reserved for bariatric surgery.

So why is a dermatology newsletter writing about an obesity drug? Because the same magnitude that makes retatrutide a medical landmark is exactly what makes it a problem for your skin. The deeper and faster the loss, the less time the face and body have to retract around the frame underneath. And because retatrutide is already being sold — unapproved — on a grey market where it's reconstituted on kitchen counters and microdosed for "anti-aging," a claim with precisely zero clinical support.¹⁵ The data deserves a sober read before the influencers finish writing the story for you.

One caveat I'm going to repeat, because it matters more than any single statistic in this issue: every Phase III number here comes from a company press release. None of it has been peer-reviewed. Lilly says the full datasets arrive at the American Diabetes Association meeting in June.^1,9 Until then, we are reading Lilly's homework, graded by Lilly. The efficacy is almost certainly real — three independent trials don't all hallucinate in the same direction — but the medical community has not yet pulled the data apart the way it eventually will.

Three Receptors, One Injection

If you read Issue #016 this part is review, so I'll keep it tight and add the piece that matters for skin. Semaglutide — Ozempic, Wegovy — hits one receptor, GLP-1. Tirzepatide — Mounjaro, Zepbound — hits two, GLP-1 and GIP. Retatrutide hits three: GLP-1, GIP, and glucagon. It is a triple-agonist, and the third target is the whole story.⁴

The first two receptors do roughly what you'd expect: blunt appetite, slow gastric emptying, and improve how the body handles glucose. Glucagon is the novel ingredient and the reason the weight loss runs so deep. Glucagon tells the liver to release stored glucose and pushes up energy expenditure — your body burns more calories at rest. Adding glucagon agonism means retatrutide doesn't only make you eat less. It makes you spend more. That is why the curve keeps falling at two years instead of flattening at one.^1,4

Here is the part the weight-loss coverage skips. Glucagon is also a catabolic hormone for amino acids — it drives the liver to break them down for fuel. We have a natural experiment for what chronic glucagon excess does to skin: a rare glucagon-secreting tumor called a glucagonoma depletes circulating amino acids and produces a characteristic rash, necrolytic migratory erythema, alongside muscle wasting.¹⁴ I am not saying retatrutide causes that — it does not, at therapeutic doses. I am saying that the receptor doing the heavy lifting on weight is the same receptor with the most direct line to your skin and your muscle. Hold that thought; we come back to it.

Three Phase III Wins in Six Months

The Phase III program is sprawling, and the names get conflated, so let's be precise. TRIUMPH is the obesity backbone. TRANSCEND is the type 2 diabetes program. SYNERGY is the dedicated liver-disease (MASH) program, which has not yet read out.⁸ Three trials have now reported topline, and they tell a consistent story.

For context, the best previous numbers in this class came from tirzepatide (roughly 21% in SURMOUNT-1) and semaglutide (roughly 15% in STEP-1).⁴ Retatrutide is the first agent to credibly approach the 30% threshold long associated with surgery. It also moved the cardiometabolic markers you'd want it to move: waist circumference down by about 9.5 inches at the top dose, with reductions in triglycerides, non-HDL cholesterol, blood pressure, and C-reactive protein.¹

Topline Isn't Peer Review

Three things keep me from waving this through unconditionally, and none of them are about the weight loss being fake. They are about how much we are allowed to conclude today.

First, the data is company-reported and unpublished. Every figure above originates from an Eli Lilly press release or investor announcement. Full datasets are promised for June.^1,2,3 Press-release topline data is not the same as a paper that statisticians, editors, and competitors have torn apart. The direction is trustworthy; the precise magnitude and the subgroup nuances are provisional.

Second, there are no cardiovascular outcomes yet. A large MACE trial — major adverse cardiac events — is running, but it has not reported. That matters because retatrutide raises resting heart rate, and "lots of weight loss" is not automatically "fewer heart attacks." We learned that lesson the slow way with earlier weight drugs. Until the outcomes trial reads out, the long-term cardiac math is an open question.⁹

Third, durability is untested. We do not yet have published retatrutide data on what happens when you stop. The semaglutide discontinuation studies are sobering — patients regained about two-thirds of lost weight within a year of stopping. There is no biological reason to expect retatrutide behaves differently. This is very likely a drug you take indefinitely, which makes its long-term safety and its skin consequences a chronic question, not a temporary one.⁴

And the conflicts are exactly what you'd expect. Lilly funded, designed, and ran every trial. The lead investigator on TRIUMPH-1 also led the Phase 2 NEJM trial and has a long-standing relationship with the company.^1,4 That doesn't make the results wrong — it makes independent replication and full publication the things to watch for.

The Side Effects Scale With the Dose

The gastrointestinal profile is the familiar one for this class, just turned up. In TRIUMPH-1, at the 12 mg dose, nausea hit 42%, diarrhea 32%, and vomiting 25%, against far lower placebo rates.¹ Most events were mild to moderate and faded over time, but they drove real attrition: AE-related discontinuation reached 11.3% at the top dose in TRIUMPH-1 and 18.2% in TRIUMPH-4.^1,2 Some of those exits, remarkably, were attributed to perceived excessive weight loss in lower-weight patients — a sentence that tells you how potent this molecule is.⁹

Then there's the heart. Retatrutide produces a dose-dependent rise in resting heart rate of roughly 6 to 7 beats per minute at the top dose, peaking around week 24 before partially settling.^4,9 Glucagon and GLP-1 both nudge the heart, so this is mechanistic, not mysterious. Whether it carries long-term cardiac cost is precisely what the unfinished outcomes trial exists to answer.

The genuinely new finding — the one a skin newsletter should care about — is dysesthesia: an abnormal sense of touch, where ordinary sensation feels wrong or uncomfortable. It did not appear in the Phase 2 trials. In Phase III it showed up clearly: 12.5% at 12 mg in TRIUMPH-1 and 20.9% at 12 mg in TRIUMPH-4, versus under 1% on placebo.^1,2,9 It was mostly mild and rarely caused anyone to quit, but it is a cutaneous, dose-dependent signal that emerged only at scale. We don't yet know its mechanism. We do know it tracks with the highest dose.

What Thirty Percent Costs Your Face

This is where the landmark drug meets the mirror. The clinical community already has a name for what happens to the face after large GLP-1 weight loss — "Ozempic face" — and we covered the mechanism in Issue #040, "The Collagen Collapse." Retatrutide doesn't introduce a new problem so much as it dials the existing one up to a setting we haven't really seen before pharmacologically.

The dose-response here is intuitive and the surgeons who manage the aftermath say it plainly. One Dallas plastic surgeon who runs a dedicated post-GLP-1 contouring program puts the threshold at around 20% body-weight loss, beyond which skin laxity becomes common — especially over age 40 — and notes that the face "loses volume faster than it can contract, resulting in a hollowed, aged appearance," an effect "amplified with higher degrees of weight loss."¹² Retatrutide routinely lands at 28 to 30%. It is, functionally, a laxity machine — not because it does anything special to skin, but because it removes the underlying volume so quickly and so completely.

Two mechanisms compound the cosmetic cost. The first is muscle. In the peer-reviewed Phase 2 body-composition substudy, patients lost up to 6.5 kg of lean mass alongside their fat — roughly 20 to 25% of total weight lost was lean tissue.⁷ Lilly frames that proportion as similar to other drugs in the class, which is fair. But the absolute lean loss is large simply because the total loss is so large, and muscle is part of what holds skin taut from beneath. The second is the glucagon angle I asked you to hold earlier: chronic glucagon-receptor agonism pressures the amino-acid pool that collagen synthesis depends on.¹⁴ That is mechanistic inference, not a measured retatrutide finding — but it is a reasonable hypothesis for why a glucagon-containing drug might tax the skin's raw materials more than a pure GLP-1 agonist.

I want to be honest about the limits of the collagen story, because I dislike when newsletters aren't. The 2025 literature on whether GLP-1 drugs directly suppress dermal collagen is genuinely conflicting. Some work describes receptor-mediated oxidative damage to fibroblasts and reduced procollagen output;¹³ other in-vitro work has found these drugs protective of dermal fibroblasts. The direct "the drug attacks your collagen" claim is not settled. What is settled is the geometry: remove 30% of a body's volume in two years and the envelope around it will not always keep up.

If you end up on this drug — and given the data, many people will — the dermatologic playbook is unglamorous but real. Slower dose titration slows the pace of loss and gives tissue time to retract. Resistance training and adequate protein intake protect lean mass, which is the single most actionable lever you have. Sun protection, hydration, and patience do the rest. For volume that's already gone, the options run from injectable fillers and fat grafting up through energy-based tightening — radiofrequency microneedling, bipolar RF, ultrasound — and, after weight stabilizes for several months, surgical contouring. None of that is a reason to avoid a drug that may add years to a high-risk patient's life. It's a reason to plan for the skin instead of being ambushed by it.

And a closing word on the grey market, because it's where most of you will first hear "retatrutide." It is not approved. It is being sold as research-grade powder, reconstituted at home, and microdosed at sub-clinical levels marketed for "longevity" and "anti-aging."¹⁵ There is no clinical evidence for skin or anti-aging benefit at any dose, let alone a fraction of one — and the same molecule being sold for your face is the one whose full-dose trials produced a heart-rate signal and a new dysesthesia signal under medical supervision. Buying it off an influencer code removes the supervision and keeps the risks.

Dr. Cole's Verdict